the EARLY TREATMENT WITH BAMLANIVIMAB ALONE DOES NOT PREVENT COVID-19 HOSPITALIZATION AND ITS POST-ACUTE SEQUELAE. A REAL EXPERIENCE IN UMBRIA, ITALY.

Background and Objective The use of monoclonal antibodies to the SARS-Cov-2 spike protein for early treatment of COVID-19 disease is being evaluated, with only phase 2 studies available, to date. Emergency authorization of bamlanivimab monotherapy was get in November 2020 by the FDA and in Mar...

Description complète

Détails bibliographiques

Auteurs principaux:	Elisabetta Schiaroli, Giuseppe Vittorio De Socio, Laura Martinelli Martinelli, lisa malincarne, Martina Savoia, Anna Laura Spinelli, Daniela Francisci
Format:	Artigo
Langue:	Inglês
Publié:	PAGEPress Publications 2021-10-01
Collection:	Mediterranean Journal of Hematology and Infectious Diseases
Sujets:	Bamlanivimab COVID-19 hospitalization real experience Umbria
Accès en ligne:	http://mjhid.org/index.php/mjhid/article/view/4690
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!